Biotech companies at World Vaccine Congress Europe 2026
Oct 19–21, 2026 Amsterdam, Netherlands ~2k attendees Website
43 biotech companies are at World Vaccine Congress Europe 2026 — 47 presentations on the program and 24 with a booth in the exhibit hall. Most represented: Tonix Pharmaceuticals (3 on the program), DIOSynVax (2 on the program), Abera Bioscience (2 on the program). 27 of them have their own page in this guide. As of Sep 26, 2026.
All 251 organizations at World Vaccine Congress Europe 2026 →
Topic
Top represented
Showing 1–14 of 43 organizations
| Organization | World Vaccine Congress Europe 2026 Attendance |
|---|---|
Tonix Pharmaceuticals Chatham, NJ | |
Biopharmaceutical company whose vaccine work includes TNX-801, a horsepox-based vaccine platform. | Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 11:30 Working Group: Vectored Vaccine Platforms: from design to improving efficacy Platforms & delivery Talk Wed Oct 21 13:15 |
DIOSynVax Cambridge, United Kingdom | |
Uses computational antigen design to develop broadly protective vaccines against influenza, coronaviruses and other viral threats. | Talk Mon Oct 19 11:15 Talk Tue Oct 20 14:00 Talk Tue Oct 20 16:00 Talk Wed Oct 21 13:45 |
Develops mucosal vaccines against serious infectious diseases on a proprietary platform of outer membrane vesicles (OMVs). | Booth Exhibiting (no floor booth listed) Talk Mon Oct 19 10:30 Talk Wed Oct 21 10:30 From Innovation to Impact: Translating OMV Vaccine Technology into Clinical Reality How a developer and a contract manufacturer take vaccines made from outer membrane vesicles, tiny bacterial bubbles, from research toward clinical trials. |
Uses its AI-Immunology platform to discover and design vaccines against bacterial and viral infections and cancer. | Booth Exhibiting at Booth 216 Talk Wed Oct 21 11:00 Talk Wed Oct 21 11:30 |
Inimmune Missoula, MT | |
Biotech designing and developing TLR agonist adjuvants and immunotherapeutics. | Talk Mon Oct 19 14:00 Talk Wed Oct 21 10:45 |
Develops circular RNA vaccines, including candidates against yellow fever and dengue. | Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 16:00 Safe and Efficacious Circular RNA Vaccines to Treat Yellow Fever and Dengue Infectious disease & AMRPlatforms & delivery |
C CreaBacVac | |
Talk Wed Oct 21 10:30 | |
SB Sagitta Biotech | |
Develops targeted viral vectors that deliver toxic payloads to solid tumors, with efficacy data in glioblastoma. | Talk Wed Oct 21 10:40 |
VG The Vaccine Group | |
Develops vaccines against zoonotic and animal diseases using herpesvirus vectors. | Chair Wed Oct 21 10:30 |
HL Hilleman Laboratories Singapore, Singapore | |
Vaccine research and development organization, founded by MSD and Wellcome, developing affordable vaccines for low- and middle-income countries. | Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 11:30 Working Group: Forging Outbreak-ready Vaccine Partnerships Infectious disease & AMRSupply, safety & access Talk Wed Oct 21 09:00 The New Geopolitics of Vaccines: Global Vaccine Manufacturing in a Fractured World How governments and industry can keep vaccines flowing fairly across borders in an emergency as countries push to make vaccines at home. Supply, safety & accessBioprocess & manufacturing Talk Wed Oct 21 12:15 Panel: The New Geography of Vaccine Innovation: Why the Next Decade of Vaccine Development Will Be Driven by LMICs Why low- and middle-income countries are becoming vaccine innovators, not just trial sites, and what funding and regional regulatory cooperation they need. |
Spanish vaccine company in the Zendal group developing and manufacturing the MTBVAC tuberculosis vaccine. | Talk Wed Oct 21 12:45 Panel Wed Oct 21 14:30 Panel: Can TB vaccines deliver on the promise? What tuberculosis vaccine trials can learn from COVID-19, flu and respiratory syncytial virus, and how to make tuberculosis a funding priority. |
Acuitas Therapeutics Vancouver, Canada | |
Develops lipid nanoparticle (LNP) delivery systems for mRNA vaccines and therapeutics, licensed to partner companies. | Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 14:15 |
Booth Exhibiting at Booth 425 Talk Tue Oct 20 14:15 | |
Develops glycoconjugate vaccines, including a K1/K2 vaccine against hypervirulent Klebsiella pneumoniae in first-in-human trials. | Booth Exhibiting (no floor booth listed) |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse World Vaccine Congress Europe 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by Terrapinn or the World Vaccine Congress. Submit a correction